Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naratuximab emtansine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Naratuximab emtansine overview
Naratuximab emtansine is under development for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma such as follicular lymphoma (FL), marginal zone lymphoma (MZL) /mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). It is administered intravenously. The drug candidate is based on Targeted Antibody Payload (TAP) technology. It was also under development for the treatment of chronic lymphocytic leukemia (CLL).
Debiopharm International overview
Debiopharm International, a subsidiary of Apes-demain SA focuses on the development and manufacture of drugs for oncology and bacterial infections. it offers complete treatment to the patients from diagnostics to treatment monitoring. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.
For a complete picture of Naratuximab emtansine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
